期刊存档
人白细胞抗原G 14 bp插入/缺失多态性和血浆可溶性人白细胞抗Ｇ原表达
吴凤霞，武丽君，罗雄燕，杨明辉，刘宁涛，库尔班江，谢传美，宋小芸，唐中，张国元，周京国，赵岩，曾小峰，袁国华吴凤霞、武丽君、罗雄燕、杨明辉、刘宁涛、库尔班江、谢传美，四川南充 川北医学院风湿免疫研究所，637000；武丽君、库尔班江、宋小芸，新疆维吾尔自治区人民医院风湿科；刘宁涛，遂宁市中心医院风湿科；赵岩、曾小峰，中国医学科学院 北京协和医学院 北京协和医院风湿科
基金项目：卫生部重大疾病研究资助项目（2008BA159B02）
摘 要:目的 检测系统性红斑狼疮（SLE）患者人白细胞抗原G（HLA-G）14 bp插入/缺失（ins/del）多态性和血浆可溶性HLA-G（sHLA-G）水平，并分析它们与SLE的关联性。方法 聚合酶链式反应（PCR）检测231例SLE患者及367名健康体检者的HLA-G 14 bp ins/del多态性的基因型分布，酶联免疫吸附法（ELISA）检测其中96例SLE患者及74名健康体检者血浆sHLA-G水平。结果 HLA-G 14 bp ins/del多态性位点和基因型频率分布在正常人组和SLE组均无统计学意义（P均＞0.05），血浆sHLA-G水平在SLE患者组为（230.2±192.2）U/ml，明显高于正常人组的（118.3±38.1）U/ml（P＝0.0001）；血浆sHLA-G水平增高的SLE患者易出现中枢神经系统受累（P＝0.007），且较血浆sHLA-G水平正常的患者病情更重（P＝0.027）。进一步分析血浆sHLA-G水平增高和正常SLE患者的HLA-G 14 bp ins/del多态性位点和基因型分布，未发现两组间有差异（P＝0.675）。结论 血浆sHLA-G水平在SLE患者中明显增高提示sHLA-G可能参与到SLE发病机制中，其水平高低主要取决于SLE病情严重性及活动性，而与HLA-G 14 bp ins/del多态性无关。
关键词:红斑狼疮，系统性； HLA抗原； 基因型
HLA-G 14 bp ins/del polymorphism and expression of plasma soluble HLA-G in patients with systemic lupus erythematosus
WU Feng-xia，WU Li-jun，LUO Xiong-yan，YANG Ming-hui，LIU Ning-tao， KUER Ban-jiang，XIE Chuan-mei，SONG Xiao-yun，TANG Zhong，ZHANG Guo-yuan，ZHOU Jing-guo，ZHAO Yan，ZENG Xiao-feng，YUAN Guo-hua.Institute of Rheumatology and Immunology，Affiliated Hospital of North Sichuan Medical College，Nanchong 637000，China
Abstract:Objective To determine the association of HLA-G 14 bp insertion/deletion polymorphism and plasma soluble HLA-G（sHLA-G）levels with systemic lupus erythematosus（SLE）. Methods Polymerase chain reaction（PCR）was performed to detect the genotypes of HLA-G 14 bp ins/del polymorphism in 231 SLE patients and 367 healthy controls，and soluble HLA-G（sHLA-G）levels were determined by enzyme-linked immunosorbent assay in 96 SLE patients and 74 healthy controls. Results No significant differences were found in HLA-G 14 bp ins/del allelic frequencies and genotype distributions between SLE patients group and the control group（P＞0.05）. However，plasma concentration of sHLA-G was significant higher in SLE patients than that in healthy controls（230.2±192.2）U/ml vs.（118.3±38.1）U/ml，P＝0.0001）. Moreover，the patients with increased levels of sHLA-G had higher incidence of central nervous system involvement（P＝0.007）and more severe disease activity（P＝0.027）in comparison with patients with normal plasma sHLA-G levels. Finally，analysis of HLA-G 14 bp ins/delpolymorphism in patients with increased sHLA-G levels revealed that there was not different from that in patients with normal sHLA-G levels（P＝0.675）. Conclusions The increased production of sHLA-G indicates that sHLA-G may play an important role in the pathogenesis of SLE，the expression of sHLA-G may be associated with disease activity and severity of lupus patients，but be independence of HLA-G 14 bp ins/del polymorphism.
Key words:Lupus erythematosus，systemic； HLA antigens； Genotype
参考文献:
[1] Apps R，Gardner L，Moffett A. A critical look at HLA-G. Trends Immunol，2008，29（7）：313－321.[PubMed]
[2] Rizzo R，Hviid TV，Govoni M，et al. HLA-G genotype and HLA-G expression in systemic lupus erythematosus：HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens，2008，71（6）：520－529.[PubMed]
[3] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum，1997，40（9）：1725.[PubMed]
[4] Bombardier C，Gladman DD，Urowitz MB，et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum，1992，35（6）：630－640.[PubMed]
[5] Hviid TV，Rizzo R，Melchiorri L，et al. Polymorphism in the 5′ upstream regulatory and 3′ untranslated regions of the HLA-G gene in relation to soluble HLA-G and IL-10 expression. Hum Immunol，2006，67（1/2）：53－62.[PubMed]
[6] Rouas-Freiss N，Marchal RE，Kirszenbaum M，et al. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells：is HLA-G the public ligand for natural killer cell inhibitory receptors？Proc Natl Acad Sci U S A，1997，94（10）：5249－5254.[PubMed]
[7] Lindaman A，Dowden A，Zavazava N. Soluble HLA-G molecules induce apoptosis in natural killer cells. Am J Reprod Immunol，2006，56（1）：68－76.[PubMed]
[8] Shiroishi M，Tsumoto K，Amano K，et al. Human inhibitory receptors Ig-like transcript 2（ILT2）and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A，2003，100（15）：8856－8861.[PubMed]
[9] Contini P，Ghio M，Poggi A，et al. Soluble HLA-A，-B，-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol，2003，33（1）：125－134.[PubMed]
[10] Baricordi OR，Stignani M，Melchiorri L，et al. HLA-G and inflammatory diseases. Inflamm Allergy Drug Targets，2008，7（2）：67－74.[PubMed]
[11] Harley JB，Kelly JA，Kaufman KM. Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol，2006，28（2）：119－130.[PubMed]
[12] Kono DH，Theofilopoulos AN. Genetics of SLE in mice. Springer Semin Immunopathol，2006，28（2）：83－96.[PubMed]
[13] Müller-Hilke B，Mitchison NA. The role of HLA promoters in autoimmunity. Curr Pharm Des，2006，12（29）：3743－3752.[PubMed]
[14] Veit TD，Cordero EA，Mucenic T，et al. Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus. Lupus，2009，18（5）：424－430.[PubMed]
[15] Chen XY，Yan WH，Lin A，et al. The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. Tissue Antigens，2008，72（4）：335－341.[PubMed]
[16] Rosado S，Perez-Chacon G，Mellor-Pita S，et al. Expression of human leukocyte antigen-G in systemic lupus erythematosus. Hum Immunol，2008，69（1）：9－15.[PubMed]
